Evidence map›Paper›PMID 38940266›Full record

ArticleJournal of extracellular vesicles2024

Adult cardiomyocytes-derived EVs for the treatment of cardiac fibrosis.

Marta Prieto-Vila, Yusuke Yoshioka, Naoya Kuriyama, Akihiko Okamura, Yusuke Yamamoto, Asao Muranaka, Takahiro Ochiya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of extracellular vesicles, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Recent advances in biomarkers for cardiac fibrosis.Frontiers in cardiovascular medicine · 2026
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marta Prieto-VilaDepartment of Molecular and Cellular Medicine, Tokyo Medical University, Tokyo, Japan.
Yusuke YoshiokaDepartment of Molecular and Cellular Medicine, Tokyo Medical University, Tokyo, Japan.
Naoya KuriyamaDepartment of Molecular and Cellular Medicine, Tokyo Medical University, Tokyo, Japan.
Akihiko OkamuraDepartment of Molecular and Cellular Medicine, Tokyo Medical University, Tokyo, Japan.
Yusuke YamamotoLaboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Asao MuranakaDepartment of Molecular and Cellular Medicine, Tokyo Medical University, Tokyo, Japan.
Takahiro OchiyaDepartment of Molecular and Cellular Medicine, Tokyo Medical University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-0776-9918

Funding

Japan Agency for Medical Research and Development JP21fk0108575Japan Society for the Promotion of Science 20F20112
6 · The paper itself

Abstract

Cardiac fibrosis is a common pathological feature of cardiovascular diseases that arises from the hyperactivation of fibroblasts and excessive extracellular matrix (ECM) deposition, leading to impaired cardiac function and potentially heart failure or arrhythmia. Extracellular vesicles (EVs) released by cardiomyocytes (CMs) regulate various physiological functions essential for myocardial homeostasis, which are disrupted in cardiac disease. Therefore, healthy CM-derived EVs represent a promising cell-free therapy for the treatment of cardiac fibrosis. To this end, we optimized the culture conditions of human adult CMs to obtain a large yield of EVs without compromising cellular integrity by using a defined combination of small molecules. EVs were isolated by ultracentrifugation, and their characteristics were analysed. Finally, their effect on fibrosis was tested. Treatment of TGFβ-activated human cardiac fibroblasts with EVs derived from CMs using our culture system resulted in a decrease in fibroblast activation markers and ECM accumulation. The rescued phenotype was associated with specific EV cargo, including multiple myocyte-specific and antifibrotic microRNAs, although their effect individually was not as effective as the EV treatment. Notably, pathway analysis showed that EV treatment reverted the transcription of activated fibroblasts and decreased several signalling pathways, including MAPK, mTOR, JAK/STAT, TGFβ, and PI3K/Akt, all of which are involved in fibrosis development. Intracardiac injection of CM-derived EVs in an animal model of cardiac fibrosis reduced fibrotic area and increased angiogenesis, which correlated with improved cardiac function. These findings suggest that EVs derived from human adult CMs may offer a targeted and effective treatment for cardiac fibrosis, owing to their antifibrotic properties and the specificity of cargo.

Indexed as

Extracellular VesiclesFibrosisMyocytes, CardiacAdultAnimalsCells, CulturedExtracellular MatrixFibroblastsHumansMiceMicroRNAsSignal TransductionTransforming Growth Factor betaMicroRNAsTransforming Growth Factor betacardiac fibrosiscardiovascular diseasescell‐free therapyEVsextracellular vesiclesmicroRNA

Identifiers

PMID38940266
PMCPMC11211925

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.